CING — Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 13
• Website: https://www.cingulate.com

Latest SEC filings for CING

• 8-K — 2026-06-16
• 8-K — 2026-06-02
• 8-K — 2026-05-19
• 8-K — 2026-05-14
• 10-Q — 2026-05-14
• 424B3 — 2026-04-28
• 8-K — 2026-04-02
• 424B3 — 2026-03-27
• 424B3 — 2026-03-24
• 8-K — 2026-03-24

Abrir análisis completo

Educational tool only — not investment advice.